Title |
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
|
---|---|
Published by |
John Wiley & Sons, Ltd, October 2012
|
DOI | 10.1002/14651858.cd000544.pub3 |
Pubmed ID | |
Authors |
Feagan, Brian G, MacDonald, John K |
Abstract |
Oral 5-aminosalicylic (5-ASA) preparations were intended to avoid the adverse effects of sulfasalazine (SASP) while maintaining its therapeutic benefits. Previously, it was found that 5-ASA drugs were more effective than placebo but had a statistically significant therapeutic inferiority relative to SASP. This updated review includes more recent studies and evaluates the effectiveness, dose-responsiveness, and safety of 5-ASA preparations used for maintenance of remission in quiescent ulcerative colitis. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 50% |
Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 127 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 2% |
United States | 2 | 2% |
Germany | 2 | 2% |
Czechia | 1 | <1% |
Unknown | 120 | 94% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 22 | 17% |
Student > Master | 14 | 11% |
Other | 12 | 9% |
Student > Bachelor | 12 | 9% |
Student > Ph. D. Student | 11 | 9% |
Other | 32 | 25% |
Unknown | 24 | 19% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 64 | 50% |
Agricultural and Biological Sciences | 10 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 7 | 6% |
Nursing and Health Professions | 5 | 4% |
Psychology | 4 | 3% |
Other | 11 | 9% |
Unknown | 26 | 20% |